( MENAFN - GlobeNewsWire - Nasdaq) Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Gender Dysphoria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Gender dysphoria market. A detailed picture of the Gender dysphoria pipeline landscape is provided, which includes the disease overview and Gender dysphoria treatment guidelines.
The assessment part of the report embraces in-depth Gender dysphoria commercial assessment and clinical assessment of the Gender dysphoria pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gender dysphoria collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. The report provides insights into: Key Questions Answered Key Topics Covered 1.
Report Introduction 2. Gender Dysphoria 3. Gender Dysphoria Current Treatment Patterns 4.
Gender Dysphoria - Analytical Perspective 5. Therapeutic Assessment 6. Gender Dysphoria Late Stage Products (Phase-III) 7.
Gender Dysphoria Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10.
Inactive Products 11. Dorm.